BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 29, 2025
Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Praecis Gets First Approval: Plenaxis In Prostate Cancer

Dec. 1, 2003
By Aaron Lorenzo
Prostate cancer patients gained a new treatment option on Nov. 25 as the FDA approved Plenaxis, a drug fully developed by Praecis Pharmaceuticals Inc. (BioWorld Today)
Read More

Pain Therapeutics Compound Begins Pivotal Program In IBS

Nov. 26, 2003
By Aaron Lorenzo

Pain Therapeutics Compound Begins Pivotal Program In IBS

Nov. 26, 2003
By Aaron Lorenzo

Genzyme Begins Pivotal Study To Broaden Synvisc's Labeling

Nov. 25, 2003
By Aaron Lorenzo

PPD Buying $25M Of Syrrx Stock As Part Of Diabetes Collaboration

Nov. 21, 2003
By Aaron Lorenzo
PPD Inc. is taking a stake in privately held Syrrx Inc. as part of a drug development deal. The companies agreed to partner their resources in further developing Syrrx-designed human dipeptidyl peptidase-IV (DP4) inhibitors for Type II diabetes and other diseases. (BioWorld Today)
Read More

Telik Presents Multiple Telcyta Studies In Ovarian, Lung Cancer

Nov. 21, 2003
By Aaron Lorenzo

Telik Presents Multiple Telcyta Studies In Ovarian, Lung Cancer

Nov. 21, 2003
By Aaron Lorenzo

PPD Buying $25M Of Syrrx Stock As Part Of Diabetes Collaboration

Nov. 21, 2003
By Aaron Lorenzo
PPD Inc. is taking a stake in privately held Syrrx Inc. as part of a drug development deal. The companies agreed to partner their resources in further developing Syrrx-designed human dipeptidyl peptidase-IV (DP4) inhibitors for Type II diabetes and other diseases. (BioWorld Today)
Read More

Sonus Reports Favorable Cancer Drug Data From Phase IIa Studies

Nov. 20, 2003
By Aaron Lorenzo

NIH Providing Funding Base For New Orleans' Life Science Growth

Nov. 20, 2003
By Aaron Lorenzo
View All Articles by Aaron Lorenzo

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 29, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing